Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Jointly provided by

  

Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.

Release date: 5/1/2024

Expiration date: 5/1/2025

Estimated time to complete: 1.0 hour


IMPORTANT NOTE: This educational course is not accredited for CME/CE credit.

Overview

Recent advances in multiple myeloma treatment include a variety of new and novel treatments. Of these, bispecific antibody therapy, a powerful form of targeted immunotherapy, has been particularly promising, achieving high response rates, helping patients achieve deeper and more sustained responses, and giving new hope to patients with multiply relapsed or refractory multiple myeloma (RRMM). For all these potential benefits, bispecific antibodies can also produce serious, potentially life-threatening, adverse events (AEs), including cytokine release syndrome (CRS), neurotoxicity, and infection. For health care providers (HCPs) looking to incorporate bispecific antibody therapy into their practices, familiarity with strategies for preventing and managing these AEs is essential.

Faculty

Jesus G. Berdeja, MD—Program Chair
Director of Multiple Myeloma Research
Greco-Hainsworth Tennessee Oncology Centers for Research
Nashville, Tennessee

Nicholas G. Barkemeyer, MPAS
Physician Assistant Certified
Tennessee Oncology
Nashville, Tennessee

Ajai Chari, MD
Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California

Amy Gebhardt—Patient Advocate
Nashville, Tennessee

Target Audience

This activity has been designed to meet the educational needs of community hematologist-oncologists and other HCPs involved in the care of RRMM patients.

Learning Objectives

After completing this activity, participants should be better able to:

  • Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
  • Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
  • Employ the recommended monitoring for treatment complications and the management strategies for bispecific antibody therapy AEs

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information

For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.

Privacy

This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.

Copyright

© 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.